Cargando…

Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil

BACKGROUND: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. METHODS: In a double-blinded crossover tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuchardt, Jan Philipp, Schneider, Inga, Meyer, Henrike, Neubronner, Juliane, von Schacky, Clemens, Hahn, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168413/
https://www.ncbi.nlm.nih.gov/pubmed/21854650
http://dx.doi.org/10.1186/1476-511X-10-145
_version_ 1782211386403717120
author Schuchardt, Jan Philipp
Schneider, Inga
Meyer, Henrike
Neubronner, Juliane
von Schacky, Clemens
Hahn, Andreas
author_facet Schuchardt, Jan Philipp
Schneider, Inga
Meyer, Henrike
Neubronner, Juliane
von Schacky, Clemens
Hahn, Andreas
author_sort Schuchardt, Jan Philipp
collection PubMed
description BACKGROUND: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. METHODS: In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y) were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA in the applied supplements was analyzed. RESULTS: The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC(0-72 h): 80.03 ± 34.71%*h), followed by fish oil rTAG (mean AUC(0-72 h): 59.78 ± 36.75%*h) and EE (mean AUC(0-72 h): 47.53 ± 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the differences in EPA bioavailability. Statistical pair-wise group comparison's revealed a trend (p = 0.086) between rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not contain any free FA. CONCLUSION: Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and taken into consideration in future trials.
format Online
Article
Text
id pubmed-3168413
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31684132011-09-08 Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil Schuchardt, Jan Philipp Schneider, Inga Meyer, Henrike Neubronner, Juliane von Schacky, Clemens Hahn, Andreas Lipids Health Dis Research BACKGROUND: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. METHODS: In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y) were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA in the applied supplements was analyzed. RESULTS: The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC(0-72 h): 80.03 ± 34.71%*h), followed by fish oil rTAG (mean AUC(0-72 h): 59.78 ± 36.75%*h) and EE (mean AUC(0-72 h): 47.53 ± 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the differences in EPA bioavailability. Statistical pair-wise group comparison's revealed a trend (p = 0.086) between rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not contain any free FA. CONCLUSION: Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and taken into consideration in future trials. BioMed Central 2011-08-22 /pmc/articles/PMC3168413/ /pubmed/21854650 http://dx.doi.org/10.1186/1476-511X-10-145 Text en Copyright ©2011 Schuchardt et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Schuchardt, Jan Philipp
Schneider, Inga
Meyer, Henrike
Neubronner, Juliane
von Schacky, Clemens
Hahn, Andreas
Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
title Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
title_full Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
title_fullStr Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
title_full_unstemmed Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
title_short Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
title_sort incorporation of epa and dha into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168413/
https://www.ncbi.nlm.nih.gov/pubmed/21854650
http://dx.doi.org/10.1186/1476-511X-10-145
work_keys_str_mv AT schuchardtjanphilipp incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil
AT schneideringa incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil
AT meyerhenrike incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil
AT neubronnerjuliane incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil
AT vonschackyclemens incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil
AT hahnandreas incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil